Dartmouth-Hitchcock Medical Center
This study is to determine whether acute treatment-associated adverse events following breast re-irradiation with aPBI are acceptably low and to assess local control following breast re-irradiation with aPBI. An exploratory aim is to assess cosmetic outcomes following breast re-irradiation with aPBI.
Inclusion Criteria 1. Patients who have histologically-confirmed, second, ipsilateral breast cancer which was diagnosed more than one year after completing breast conserving therapy. 2. Patients must have received prior radiotherapy to the breast 3. Patients must have an intact, involved breast. 4. Patients must meet ASTRO 2023 guidelines for a strong recommendation for partial breast irradiation. * Grade 1-2 disease * ER-positive histology * Tumor size up to 2 cm * Patient's age 40 or older 5. Patients who will undergo breast radiation therapy at D-H Lebanon, D-H St. Johnsbury,…
aPBI, which is routinely used to treat patients who have previously not been irradiated, with a dose of 30 Gy in 5 fractions using a VMAT technique.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.